Epidemiology

M.J. Alter, H.S. Margolis,K. Krawczynski, F.N. Judson, A. Mares, W.J. Alexander, P.Y. Hu, J.K. Miller, M.A. Gerber, R.E. Sampliner, E.L. Meeks, M.J. Beach, "The natural history of community acquired hepatitis-C in the United States," New England Journal of Medicine, 327:1899-1905, 1992. (Total citations through October 1994: 76) This paper reports the results of a study tracking the onset and course of hepatitis C virus (H

Written byMiriam Alter
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

This paper reports the results of a study tracking the onset and course of hepatitis C virus (HCV) infection in patients over a four- to six-year period.

"We looked at the natural history of the disease--namely what happens over time with respect to infection and clinical symptoms," says Miriam Alter, chief of the epidemiology section of the hepatitis branch at the Centers for Disease Control and Prevention (CDC) in Atlanta. "We found that 62 percent of the patients developed chronic hepatitis and that all of them remained persistently infected even in the absence of liver disease or inflammation."

From an epidemiological perspective, this study proved significant, Alter explains, since "it showed that the majority of cases did not contract the disease from transfusions, which are believed to be the most common mode of spread. Most people get it [HCV] as a result of community-based exposure--sharing contaminated needles, for instance, or ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies